Safety and Immunogenicity of an Inactivated Influenza A/H5N1 Vaccine Given with or without Aluminum Hydroxide to Healthy Adults: Results of a Phase I–II Randomized Clinical Trial

This publication has 23 references indexed in Scilit:

• Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults
  Vaccine, 2009
• Effects of Adjuvants on the Safety and Immunogenicity of an Avian Influenza H5N1 Vaccine in Adults
  The Journal of Infectious Diseases, 2008
• Preparing for a possible pandemic: influenza A/H5N1 vaccine development
  Current Opinion in Pharmacology, 2007
• Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model
  Vaccine, 2007
• Inactivated Whole Virus Influenza A (H5N1) Vaccine1
  Emerging Infectious Diseases, 2007
• Safety and Immunogenicity of Nonadjuvanted and MF59-Adjuvanted Influenza A/H9N2 Vaccine Preparations
  Clinical Infectious Diseases, 2006
• Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial
  The Lancet, 2006
• Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine
  New England Journal of Medicine, 2006
• Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use
  Virus Research, 2004
• Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza
  The Lancet, 2001